United Kingdom· GB-APID-39653811000001109
Adakveo 100mg/10ml concentrate for solution for infusion vials
A crizanlizumab product containing crizanlizumab, registered in United Kingdom by Novartis Pharmaceuticals UK Ltd. The same ATC class is registered in 7 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Crizanlizumab is registered in 7 of 19 countries.
Countries holding a registration under ATC B06AX01 (crizanlizumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 6 of them publish a price we can compare per daily dose
Crizanlizumab · ATC B06AX01
7 / 19 countries
- Belgiumprice
- Finlandprice
- Franceprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Crizanlizumab
- Manufacturer
- Novartis Pharmaceuticals UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- B06AX01
- ATC class
- Crizanlizumab
- Defined daily dose
- 12.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin7612797525500
- gtin7613421029968
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Crizanlizumab in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesADAKVEONovartis Pharmaceuticals Corporation
- BelgiumAdakveo 10 mg/mlNovartis Europharm
- SpainADAKVEO 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONNovartis Europharm Limited
- FinlandAdakveoNovartis Europharm Limited
- FranceADAKVEO 10 mg/mL, solution à diluer pour perfusionNOVARTIS EUROPHARM (IRLANDE)
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d7e83ce3-3e60-4ec6-8399-f84a5a5de51c GET /v1/drugs/d7e83ce3-3e60-4ec6-8399-f84a5a5de51c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "39653811000001109",
"desc": "Adakveo 100mg/10ml concentrate for solution for infusion vials (Novartis Pharmaceuticals UK Ltd)",
"form": "Solution for infusion",
"vpid": "39964611000001100",
"source": "dmd",
"vtm_id": "830203004",
"strength": "10 mg",
"substance": "Crizanlizumab",
"ingredient": "Crizanlizumab",
"supplier_code": "2920101000001102"
}See everything about crizanlizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.